"The new study — from an international consortium comprising 19 studies from 16 countries with more than 45,000 participants — found that higher circulating blood levels of omega-3 fatty acids were associated with a nearly 10 percent lower risk of a fatal heart attack, on average, compared with lower levels. The participants with the highest level of omega-3s in their blood had the greatest risk reduction — a more than 25 percent lower risk of having a fatal heart attack, the study found."
Now just imagine what a pill of a high concentration of EPA in a pure form will do.
Much smaller hiccup than I thought. Not many shorts were able to cover because not enough stops at $2.00. Much smarter retail holders here. There will be a very significant squeeze in the future. All depends on interim. If continuation at interim shorts will try to use that as an exit. I would not want to be in that position.
Will probably take out stops at $2.00, go below $2.00, then recover and close at $2.06. AJMO. Let's see if big money takes advantage of a buying opportunity. Will be interesting.
And the plot thickens:
" Valvani tasked JOHNSTON with obtaining highly confidential and material nonpublic information from the FDA about pending generic drug ANDAs and related citizen petitions, information that FDA employees were not authorized to disclose to the public. An ANDA, or Abbreviated New Drug Application, is the process by which a pharmaceutical company can apply to the FDA for approval to sell a generic version of a brand name drug. In many cases, the brand name drug company files a citizen petition with the FDA challenging the generic drug company’s ANDA and arguing that the FDA should deny it. The FDA’s decision to approve a generic drug ANDA typically has a positive impact on the stock price of the company receiving approval, and a negative impact on the stock price of the company producing the brand name drug."
Be interesting to see how deep this goes. Did it have anything to do with Amarins 5 year NCE approval ? Note bottom of next to last paragraph,trading in Watson was affected.
Washington D.C., June 15, 2016 — The Securities and Exchange Commission today announced insider trading charges against two hedge fund managers and their source, a former government official accused of deceptively obtaining confidential information from the U.S. Food and Drug Administration (FDA). A third hedge fund manager working at the same investment advisory firm as the alleged insider traders was charged with falsely inflating assets in portfolios he managed.
The SEC alleges that Sanjay Valvani reaped unlawful profits of nearly $32 million for hedge funds investing in health care securities by insider trading on tips he received from Gordon Johnston, who worked at the FDA for a dozen years and remained in close contact with former colleagues while working for a trade association representing generic drug manufacturers and distributors. Johnston concealed his separate role as a hedge fund consultant and obtained confidential information about anticipated FDA approvals for companies to produce enoxaparin, a generic drug that helps prevent the formation of blood clots. Johnston allegedly funneled to Valvani the details of his conversations with FDA personnel, including a close friend he mentored during his time at the agency. Valvani then traded in advance of public announcements concerning FDA approvals for such companies as Momenta Pharmaceuticals, WATSON Pharmaceuticals, and Amphastar Pharmaceuticals.
“We allege that Valvani’s formula for trading success was tapping Johnston to abuse his position of trust as a generic industry representative to the FDA and underhandedly obtain confidential information from his friends and former colleagues at the FDA,” said Andrew J. Ceresney, Director of the SEC’s Division of Enforcement. “Valvani and his hedge funds made millions by trading on nonpublic FDA drug approval information
Absolutely, looking more closely at older trial data should give insight into current trial results. The proof is in the pudding.
AZN, FDA twice, disgruntled investors, and now Watson. Next up FDA yet again, R- it results will expose their faulty science. Putting influence and grudges before science is always a mistake. AJMO.
Little retail shorts are always the last to know. Perhaps you didn' t the email from that shorting house rag you read? Hahaha.
Fishy Fingers predicted a squeeze has begun. To some extent may be true but shorting again at the top is happening. If hedge funds try to get in early to hedge their short positions price should stay close to where it is. We shall see soon enough. So you are right, new interest and buying is the key